Mouse Myelin Oligodendrocyte Glycoprotein (MOG)

Mouse Myelin Oligodendrocyte Glycoprotein (MOG)
Catalog number: B2011183
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 µg
Molecular Weight or Concentration: 14.2 kDa
Supplied as: Solution
Applications: molecular tool for various biochemical applications
Storage: Lower than -20C
Keywords: Myelin Oligodendrocyte Glycoprotein, Recombinant mouse MOG (1-125)
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Sinha S, Subramanian S, Emerson-Webber A, Lindner M, Burrows GG, Grafe M, Linington C, Vandenbark AA, Bernard CC, Offner H. Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG J Neuroimmune Pharmacol. 2010 Jun;5(2):231-9.
2: Xu Z, Lin CC, Ho S, Vlad G, Suciu-Foca N. Suppression of Experimental Autoimmune Encephalomyelitis by ILT3.Fc J Immunol. 2021 Feb 1;206(3):554-565.
3: Pacini G, Ieronymaki M, Nuti F, Sabatino G, Larregola M, Aharoni R, Papini AM, Rovero P. Epitope mapping of anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a mouse model of multiple sclerosis: microwave-assisted synthesis of the peptide antigens and ELISA screening J Pept Sci. 2016 Jan;22(1):52-8.
4: Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J. Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis J Mol Med (Berl). 1997 Feb;75(2):77-88.
5: Nicoletti F, Mazzon E, Fagone P, Mangano K, Mammana S, Cavalli E, Basile MS, Bramanti P, Scalabrino G, Lange A, Curtin F. Prevention of clinical and histological signs of MOG-induced experimental allergic encephalomyelitis by prolonged treatment with recombinant human EGF J Neuroimmunol. 2019 Jul 15;332:224-232.
6: Pham-Dinh D, Jones EP, Pitiot G, Della Gaspera B, Daubas P, Mallet J, Le Paslier D, Fischer Lindahl K, Dautigny A. Physical mapping of the human and mouse MOG gene at the distal end of the MHC class Ib region Immunogenetics. 1995;42(5):386-91.
7: Malavé CM, Lopera-Madrid J, Medina-Magües LG, Rocke TE, Osorio JE. Impact of Molecular Modifications on the Immunogenicity and Efficacy of Recombinant Raccoon Poxvirus-Vectored Rabies Vaccine Candidates in Mice Vaccines (Basel). 2021 Dec 4;9(12):1436.
8: Devaux B, Enderlin F, Wallner B, Smilek DE. Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide J Neuroimmunol. 1997 May;75(1-2):169-73.
9: Yang L, Liu Z, Ren H, Zhang L, Gao S, Ren L, Chai Z, Meza-Romero R, Benedek G, Vandenbark AA, Offner H, Li M. DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury Metab Brain Dis. 2017 Oct;32(5):1395-1402.
10: Liñares D, Echevarria I, Mañá P. Single-step purification and refolding of recombinant mouse and human myelin oligodendrocyte glycoprotein and induction of EAE in mice Protein Expr Purif. 2004 Apr;34(2):249-56.

Products Related to
Mouse Myelin Oligodendrocyte Glycoprotein (MOG) can be found at Proteins